Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Common Equity: 2014-2024

Historic Common Equity for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$6.8 million.

  • Cartesian Therapeutics' Common Equity fell 4866.49% to -$35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.8 million, marking a year-over-year decrease of 4866.49%. This contributed to the annual value of -$6.8 million for FY2024, which is 98.45% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Common Equity of -$6.8 million as of FY2024, which was up 98.45% from -$440.2 million recorded in FY2023.
  • Cartesian Therapeutics' 5-year Common Equity high stood at $93.8 million for FY2022, and its period low was -$440.2 million during FY2023.
  • Over the past 3 years, Cartesian Therapeutics' median Common Equity value was -$6.8 million (recorded in 2024), while the average stood at -$117.7 million.
  • In the last 5 years, Cartesian Therapeutics' Common Equity soared by 316.62% in 2022 and then crashed by 569.14% in 2023.
  • Cartesian Therapeutics' Common Equity (Yearly) stood at -$18.0 million in 2020, then soared by 225.07% to $22.5 million in 2021, then soared by 316.62% to $93.8 million in 2022, then crashed by 569.14% to -$440.2 million in 2023, then soared by 98.45% to -$6.8 million in 2024.